Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)
Barinthus Biotherapeutics' (BRNS) quarterly Convertible Debt came in at $44.7 million in Q4 2020.
Barinthus Biotherapeutics (BRNS) Convertible Debt (2020) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 1 years of Convertible Debt data on file, last reported at $44.7 million in Q4 2020.
- Quarterly Convertible Debt changed N/A year-over-year to $44.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $44.7 million (changed N/A YoY) and the FY2020 annual result came in at $44.7 million, changed N/A from the prior year.
- Convertible Debt held at $44.7 million in Q4 2020.
- In the past five years, Convertible Debt ranged from a high of $44.7 million in Q4 2020 to a low of $44.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 44.70 Mn |